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Abstract
The aims of the investigation were to establish for the first time (i) clinical efficacy and (ii)
pharmacokinetic profile of meloxicam intravenously (IV) administered in male Mediterra-
nean buffalo calves after surgical orchiectomy. The study was performed on 10 healthy buf-
falo calves, between 4 and 5 months old and between 127 and 135 kg of body weight (b.w.).
An IV injection of 0.5 mg/kg b.w. of meloxicam was administered in six calves (treated
group, TG) immediately after surgery; the other four animals were used as untreated control
group (CG). The clinical efficacy of meloxicam was evaluated pre- and post-surgery by mon-
itoring respiratory rate (RR), heart rate (HR), rectal temperature (T˚C), serum cortisol levels
(SCL) and pain score (PS). Significant inter-groups differences were detected at sampling
times (T): 4 hour (h) for RR (P<0.05), at T1-4-6-8 h for PS (P<0.05) and at T4-6-8 h for SCL
(P < 0.0001). Regarding the mean intra-group values observed pre (T0) and post-surgery
(from T15 min to T72 h), significant difference between the groups were found for RR
(P<0.01), PS and SCL (P<0.05). The pharmacokinetic profile was best fitted by a two-com-
partmental model and characterized by a fast distribution half-life and slow elimination half-
life (0.09 ± 0.06 h and 21.51 ± 6.4 h, respectively) and meloxicam mean concentrations at
96 h was of 0.18 ± 0.14 μg/mL. The volume of distribution and clearance values were quite
low, but reasonably homogenous among individuals (Vdss 142.31 ± 55.08 mL/kg and ClB
4.38 ± 0.95 mL/kg/h, respectively). The IV administration of meloxicam in buffalo calves
shows encouraging effects represented by significant and prolonged analgesic effects, sig-
nificant reduction of SCL as well as similar pharmacokinetic profile to bovine calves.
Introduction
The European population of domestic buffalo (Bubalus bubalis) counts of approximately
395.000 heads [1], and Italy represents, with his 369.352 heads of Mediterranean buffalo, the
main rearing country (95%) [2]. Primarily characterized by mozzarella cheese production [2],
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buffalo’s breeding in Italy, recently has also recorded a significant growing of the beef buffalo’s
market [3,4]. As widely described for bovine [5,6], in order to reduce aggression, sexual activ-
ity, and incidence of dark-cutting carcasses, meat production often forces veterinary practi-
tioners to castration of young buffalo male calves. While in bovine, during minor surgical
procedures, the pain and welfare management are well-established on practice for their ethical
implications and impact on productivity [7], on buffalo these aspects, as well as clinical related
procedures, are still truly rare [8,9].
In general, observation of behavioural changes (e.g. abnormal standing-time, lying-time or
posture, reduced walking time) associated with clinical triage monitoring (i.e. respiratory-rate,
hearth-rate and temperature) are common parameters evaluated by the veterinary practition-
ers in field, although their accuracy to reflect pain perception is recognised as low [9,10,11].
On the other hand, the evaluation of some haemato-biochemical parameters is instead recom-
mended as the most reliable method to evaluated welfare in animals [7,12] and serum cortisol
level can be considered as the analytic, neuroendocrine parameter indicative of animal stress,
due to the direct influence on the corticosteroids release in the blood. Indeed, it is widely
proved that serum cortisol concentration tends to rise when an increased activity from noci-
ceptor is elicited by a pain stimulus [13].
As reported in literature, pain perception in cows can be significantly reduced by adminis-
tration of non-steroidal anti-inflammatory drugs (NSAIDs) often associated to the most com-
mon anaesthetic protocols during several minor and major surgical procedures [7]. NSAIDs
exert anti-inflammatory action through variable inhibition of the cyclooxygenase iso-enzymes
(COX-1 and -2). Meloxicam belongs to this category of drugs and can be considered a prefer-
ential inhibitor of COX-2: the isoform greatly up-regulated in presence of inflammatory sti-
muli [14,15]. Since a long time, meloxicam properties and effects were investigated in several
domestic species including dogs [16], cats [17], camels [18] and cows [7,19,20,21]. Its use is
approved for cattle in EU-countries, as well as in several non-EU-countries (e.g. Canada, New
Zealand, Australia); it is often recommended for endotoxicosis [22] and mastitis treatments
[23] or pain relief after several surgical procedures in cows and calves [20,21,24]. In the latters,
the administration of meloxicam at 0.5 mg/kg IV or intramuscular (IM) decreases behavioural
and physiological responses to pain and distress associated with dehorning [25,26,27]. More-
over, its pharmacokinetic profile and its effects on behaviour and performance suggest that
these may last for several days after administration [21]. In young and adult cattle, meloxicam
demonstrated a high oral bioavailability and long elimination half-life, providing an effective
and long-lasting analgesia [28]. At present, meloxicam is commonly used in buffalo practice,
although no studies about its clinical efficacy, pharmacokinetics or pharmacodynamics have
been published so far.
Considering the premises, the goals of the present investigation were to establish (i) clinical
efficacy and (ii) pharmacokinetic profile of meloxicam IV administered in male buffalo calves
after surgical orchiectomy.
Materials and methods
Animals
Ten male buffalo calves, 3 and 4 months of age (median = 3.65 months), 127 and 135 kg of
body weight (median = 130 kg), reared in the same breeding farm in Caserta district (Southern
Italy), were enrolled for this study.
The animals were randomly chosen from a group of 35 buffalo male calves and were indi-
vidually submitted to a complete clinical examination and blood samples for routine haemato-
biochemical investigations (data non shown) to verify the general good health status. One
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week before the orchiectomy, 4 calves were chosen as negative control group among the 10
selected animals (CG, untreated with meloxicam after castration), using a random number-
generated software package (Microsoft Excel); the remaining 6 buffaloes were identified as
treated group (TG, treated with meloxicam after castration). Both the groups (TG and CG),
were place in one, roofed, common paddock of ~ 50 m2 (~ 10 m × 5 m) and they were fed with
a total mixed ratio including hay, silage and a multi-vitamin integrator one time a day; water
was provided ad libitum. During the week before the castration, the investigators, to reduce
the influence of human presence on animals’ behavior and stress levels, daily handled all the
animals. Respiratory rate (RR), hearth rate (HR) and rectal temperature (T˚C) were also daily
recorded in order to get the calves used to the clinical procedures.
Drugs administration and surgical procedure
Two animals every 96h were castrated (5 groups of 2 calves). One h before surgery (T0), after
trichotomy and surgical scrub of the jugular region [29], all the buffaloes received an IV cathe-
ters (14 Gauge, L/A long-term catheter, Anicath, Millipledge, UK), for drug administration
and blood samples collection. Catheter was flushed with 10 mL of NaCl 0.9% after each use;
calves were IM treated with a 5 mL of oxytetracycline (Oxtra MV 10, Fatro, Ozzano, Italy)
after blood collection.
Animals were sedated with 5 μg/kg b.w. of dexmedetomidine IV (DexDomitor, Ve´toquinol,
Ozzano, Italy); they also received 4.5 mL of Lidocaine 2% (Zoetis Italia, Roma, Italy), injected
into each spermatic cord, and further 1 mL in the incision line. Waiting for drugs effects,
calves were placed in right lateral recumbency, and surgical field was prepared by scrubbing
the scrotal, inguinal and perianal areas according to Desrosches guidelines [29]. Surgical orchi-
ectomy was performed according to the procedure described by Weaver et al. [30]. The surgery
was considered concluded after the removal of both testicles and the topic application of oxyte-
tracyclin (Neo spray CAF, Intervet, Milano Italy); then all the calves received 0.05 mg/kg b.w
of atipamezole IV (Atipam, Dechra, Northwich, UK) to antagonize the sedative and TG
received a single dose of 0.5 mg/kg b.w. of meloxicam IV (Metacam1 20 mg/mL, Boeringher
Ingelheim Vetmedica Inc. Ingelheim am Rhein, Germany). Subsequently blood samples were
routinely collected two times (5 and 10 min after surgery) to perform venous blood gas analy-
ses (using i-STAT analyser, Abbott, Worcester, US) to monitor the acid-base balance of the
patients.
Clinical procedures
At T0, all the buffalo calves received on additional individual clinical examination to confirm
the good health status and to verify the serum cortisol levels (SCL) pre-surgery; moreover, they
were scored according to physical status scale of the American Society of Anaesthesiologists to
predict operative risk [31]. At the same time, calves were also scored with a unidimensional,
composite, pain scale validated for cows [32]. Briefly, the scoring system tracked five behav-
ioral changes (1-locomotion, 2-interactive behaviour, 3-activity, 4-appetite and 5-miscella-
neous behaviours) by an ordinal point scale, ranged from 0 (normal) to 2 (totally abnormal),
and applied to each parameter, as specified in Table 1. Each subject received 5 minutes (min)
of continuous monitoring and could achieve a maximum cumulative pain score (PS) of 10
points. All the scorings were independently and blinded performed by three observers. The
observers were placed (one per corner) within the animals’ paddock, approximately 25 min
before the evaluation, in order to adapt the calves to their presence.
After surgery, clinical efficacy of meloxicam was evaluated on regular base by means of RR,
HR, T˚C and PS detection. The parameters (RR, HR, T˚C) were always assessed by the same 2
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investigators (one per animal), at times (T) 15, 30, 45 min and 1, 1.5, 2, 4, 6, 8, 12, 24, 36, 48
and 72 h post-orchiectomy; at the same times, calves received a blood sample collection for
SCL evaluation. RR was evaluated observing the chest-abdominal movements on the right side
of the calves, HR using a stethoscope (Litmann Master Classic II, 3M Health Care, Minnesota)
placed at level of mitral valve and T˚C with electronic thermometers (Digi-Vet SC10, Kruuse;
Denmark). The same investigator recorded the previous parameters 3 times and the mean
value was considered for statistical analysis. Finally, each animal received a further complete
clinical exanimation and an additional blood sample was collected to define its health status
before the dismissal (T96 h).
All the procedures performed followed the common good clinical practices [33] and received
an institutional approval by Ethical Animal Care and Use Committee of University of Naples
“Federico II” (Protocol No. 67990/2015); moreover the farmer was previously informed and in
agreement with purposes and methods used.
Serum cortisol analysis
All the blood samples were placed into serum tubes (Vacutainer1, Becton and Dickinson,
Franklin Lakes, US) and centrifuged to obtain the sera (908 g × 15 min). Cortisol concentra-
tions were measured on serum, using a solid phase competitive chemiluminescent enzyme
immunoassay and an automated analyser system (Immulite 1000 Cortisol, Siemens Medical
Solution Diagnostic) according to the procedure described by Coetzee et al. [21]. A sample
Table 1. Pre- and post- orchiectomy UNESP-Botucatu unidimensional pain scale used at each sam-
pling time.
Parameters Score/Criterion
Locomotion (0) Walking with no obviously abnormal gait
(1) Walking with restriction, ma be with hunched back and/or short steps
(2) Reluctant to stand up, standing up with difficulty or not walking
Interactive behaviour (0) Active: attention to tactile and/or visual and/or audible environmental stimuli;
when near other animals, can interact with and/or accompany the group
(1) Apathetic: may remain close to other animals, but interacts little when
stimulated
(2) Move less frequently in the pasture or only when stimulated
Activity (0) Moves normally
(1) Restless, moves more than normal or lies down and stands up with
frequency
(2) Move less frequently in the pasture or only when stimulated
Appetite (0) Normorexia and/or rumination
(1) Hyporexia
(2) Anorexia
Miscellaneous
behaviours
• Wagging the tail abruptly and repeatedly
• Licking the surgical wound
• Moves and arches the back when in standing posture
• Kicking/foot stamping
• Hind limbs extended caudally when in standing posture
• Head below the line of spinal column
• Lying down in ventral recumbency with full or partial extension of one or both
hind limbs.
• Lying down with the head on/close to the ground
• Extends the neck and body forward when lying in ventral recumbency
(0) All of above described behaviours are absent
(1) Presence of 1 of the behaviours described above
(2) Presence of 2 or more of the behaviours described above
https://doi.org/10.1371/journal.pone.0187252.t001
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volume of 100 μL was used for each assay. The calibration range was 28–1380 nmol/L and the
analytical sensitivity was 5.5 mmol/L.
Meloxicam determination
The sera, obtained from all the blood samples performed, were also used to determine the
meloxicam concentration and pharmacokinetics. Meloxicam was extracted with a liquid-liq-
uid procedure from sera of TG according to the method described by Gao et al. [34] and vali-
dated in the laboratory. The meloxicam serum quantification was performed by HPLC system
that included a binary pump, an autosampler, a Peltier column oven set at 20˚C and an UV/
Visible detector (Series 200, Perkin Elmer, Italy) set at 360 nm of wavelength.
The drug separation was achieved by Zorbax column C18 (150x4.6, 3.5 μm, Agilent Tech-
nologies, USA) with adequate pre-column. A gradient HPLC method was used for the analysis.
The mobile phase consisted of a mixture of water, 0.5 mL/L phosphoric acid and 0.75 mL/L
triethylamine (A) and methanol (B) with a flow rate of 1 mL/min. The HPLC gradient was (A:
B, v/v) 35:65 for 7 min; 0:100 in 1 min; 0:100 for 3 min; 30:65 in 1 min and 30:65 for 4 min to
re-equilibrate the system.
The analytical standard of meloxicam sodium salt hydrate (purity grade 99%) was provided
by Sigma Aldrich (Italy). All reagents and solvents were purchased from Panreac Sa (Italy).
The analytical method was validated intra-laboratory using a set of parameters (linearity,
accuracy and precision, limit of quantification, i.e. LOQ, limit of detection, i.e. LOD and selec-
tivity) that were in compliance with the recommendations defined by the European Commu-
nity [35] and with the international guidelines [36]. The calibration curves were prepared with
spiked solutions obtained diluting the original stock solution of meloxicam (1 mg/mL) in buf-
falo blank serum to achieve concentrations ranging from 0.01 to 10 μg/mL. The correlation
coefficients (r) resulted > 0.99 for 3 replicates.
The precision (repeatability) and accuracy were determined by analysing blank samples
(n = 6 for each concentration) that were spiked with 0.01, 1 or 10 μg/mL. The results fell within
the accepted ranges for precision (8.9%, 11.3% and 4.5% for 0.01 μg/mL, 1 μg/mL and 10 μg/
mL, respectively) and accuracy (108.6%, 109.1% and 108.5% for 0.01 μg/mL, 1 μg/mL and
10 μg/mL, respectively). A LOQ value of 0.01 μg/mL was defined. The LOD was 0.045 ng/mL.
The specificity of the method was demonstrated by the absence of interference in 20 blank
serum samples at the meloxicam retention time.
Pharmacokinetic analysis
Pharmacokinetic parameters were deduced from serum concentration-time data using soft-
ware (WinNonLin Prof 6.3, Pharsight Corporation, USA) which allows compartmental and
non-compartmental analyses of the experimental data. Visual inspection of the curve, residual
analysis and minimum Akaike’s information criterion estimation [37] were used to choose the
model best fitting the data. All data points were weighted by the inverse square of the fitted
value. The disposition of meloxicam following IV administration was described by a classical
two-compartments model [38].
Statistical analysis
Clinical variables (RR, HR, T˚C and PS), SCL and pharmacokinetic parameters were analyzed
by standard descriptive statistics; normality was assessed using histograms, normal probability
plots and Shapiro Wilk tests. Data were expressed as absolute numbers, percentage, median
and range, or mean ± standard deviations (SD). For the pharmacokinetic parameter of half-
lives harmonic means with pseudo-standard deviations (SE) were calculated using a jack-knife
Meloxicam in Mediterranean buffalo calves
PLOS ONE | https://doi.org/10.1371/journal.pone.0187252 October 27, 2017 5 / 14
technique suggested by Lam et al. [39]. Regarding the clinical parameters (RR, HR, T˚C and
PS) and SCL, differences inter- (TG vs. CG, at each sampling time) and intra- groups (T0 vs.
mean value from T15 min to 72 h) were compared using Repeated-Measures Factorial
ANOVA and nonparametric Mann-Whitney U test, respectively. Correlation between mean
values of the continuous variables (RR, HR, T˚C, PS and CS) at each sampling time was also
investigated both for TG and for CG by means of non-parametric Spearman’s rank correlation
test (intra-group). As described by Taylor [40], correlation coefficients (rs) of rs 0.35 were
scored as weak, rs between 0.67 and 0.36 as moderate, between 0.89 and 0.68 as high and rs
0.9 as very high.
Regarding PS, inter-rater agreement between the quantitative measures of the three differ-
ent observers was also calculated using the intraclass correlation coefficient (ICC) based on a
two-factor mixed-effects model and type absolute agreement, according to Montgomery et al.
[41].
Probabilities < 0.05 were considered as significant. All statistical analyses were performed
using dedicated software (SPSS, Version 17.0, Chicago, IL).
Results
Clinical parameters and serum cortisol
All the animals submitted to ASA classification were included in the Class I. No adverse effects
were observed during and after meloxicam administration in the buffalo calves enrolled. All of
them presented scrotal oedema due to the surgery procedures, spontaneously recovered within
24–36 h after surgery (median = 28.5 h).
The overall mean RR values recorded were significantly lower (P< 0.001) in TG
[19.5 ± 4.0, breath per min (bpm) ±SD] than CG (23.7 ± 6.4 bpm). Comparing the two groups
at each sampling time, TG showed significant lower values than CG at T4 h after surgery
(19.4 ± 3.6 and 27.0 ± 2.4, respectively; P< 0.05).
Instead, the mean intra-group values observed pre- (T0) and post-surgery (average from
T15 min to T72 h) revealed significant lower values within TG (T0 = 25.7 ± 4.9 bpm vs. mean
T15 min-T72 h = 19.0 ± 3.5 bpm; P< 0.01) than CG (T0 = 31.0 ± 9.2 bpm vs. mean T15 min-
T72 h = 23.1 ± 5.9 bpm). No inter- (overall and partial values) or intra-groups significant dif-
ferences were instead recorded for HR and T˚C.
Regarding the PS, a near perfect agreement between the observers was found (ICC = 0.97,
P< 0.0001; CI95 = 0.94 to 0.98). The mean overall pain scores recorded were significantly
lower (P< 0.05) in TG (3.5 ± 3.3 points) than CG (4.9 ± 3.5 points). Comparing the two
groups at each sampling time, TG showed significant lower values than CG at T1h
(TG = 6.8 ± 0.9 vs. CG = 8.0 ± 0.8; P< 0.05), T4h (TG = 2.3 ± 0.5 vs. CG = 6.5 ± 1.9; P< 0.05),
T6h (TG = 1.7 ± 0.7 vs. CG = 6.0 ± 1.6; P< 0.05) and T8h (TG = 2.3 ± 0.2 vs. CG = 5.0 ± 1.1; P
< 0.05) after surgery. A significant difference between the mean intra-group values observed
pre- (T0) and post-surgery (average from T15 min to T72 h) were detected both within TG
(T0 = 0.6 ± 0.4 points vs. T15 min-T72 h = 3.7 ± 3.3 points; P< 0.05) and CG (T0 = 0.3 ± 0.0
points vs. T15 min-T72 h = 5.2 ±3.3 points; P< 0.01).
The overall mean SCL values recorded were significantly lower (P< 0.01) in TG
(26.8 ± 22.6 nmol/L) than CG (34.1 ± 18.6 nmol/L). Comparing the two groups at each sam-
pling time, TG showed significant lower values than CG at T4h (TG = 14.4 ± 7.0 vs.
CG = 47.4 ± 8.4; P< 0.0001), T6h (TG = 11.0 ± 4.7 vs. CG = 42.2 ± 7.3; P< 0.0001) and T8h
(TG = 8.0 ± 4.8 vs. CG = 37.4 ±4.0; P< 0.0001, Fig 1). The mean intra-group values observed
pre- (T0) and post-surgery (average from T15 min to T72 h) were significantly higher in CG
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(T0 = 22.7 ± 6.0 vs. mean T15 min-T72 h = 34.9 ± 18.9 nmol/L; P< 0.05), than in TG
(T0 = 24.6 ± 9.2 vs. mean T15 min-T72 h = 27.0 ± 23.3 nmol/L).
Finally, a very high correlation was detected between SCL and PS both in TG (rs = 0.97; P<
0.01) and CG (rs = 0.95; P< 0.01); instead it was moderate between SCL and T˚C in CG (rs =
0.75; P< 0.01).
Meloxicam concentrations and pharmacokinetic analysis
Mean serum concentration of meloxicam in 6 buffaloes is shown in Fig 2. The mean concen-
tration at the first sampling time was 9.39 ± 2.39 μg/mL. Then, there was a decreased in plasma
concentration and at 0.75 h mean value was 3.81 ± 1.78 μg/mL. Successively, concentrations
remained in a mean range between 3.91–2.24 μg/mL till 12 h after treatment. From 24 to 96 h
meloxicam concentration progressively decreased from 1.88 ± 0.53 μg/mL to 0.18 ± 0.14 μg/
mL. Results from all subjects were best fitted by a two-compartmental model and Table 2
reports all the results.
Discussion
To the best of the authors’ knowledge, in this paper the clinical efficacy and pharmacokinetics
of meloxicam is investigated for the first time in buffalo calves. The legal inclusion of buffalo
within the bovine specie by the EU since 2009 [42], promoted the use of drugs manufactured
for bovine in these ruminants without scientific proves of their efficacy; for this reason, the
authors used a careful and methodical approach for the evaluation of the outcomes of a drug
originally produced for dairy cows, as performed in previous studies [43,44].
In cow calves, after minor surgical procedures (e.g. castration, dehorning), meloxicam
administration can significantly reduce pain, stress and increase profitability by increasing
body average daily gain and reducing susceptibility to disease [20,21]. Meloxicam can be
administered by two routes in cattle: oral and parenteral. Although the oral one demonstrated
a good applicability, bioavailability and extended effects [19,28], it needs to be administered 12
h before surgery to coincide with the peak of drug concentrations [19]. In our experimental
condition, the choice of IV administration was performed both because of the faster positive
Fig 1. Mean serum cortisol levels pre- (T0) and post- orchiectomy (from T15m to T72h). TG = treated
groups; CG = control group; min = minutes; h = hours;T = time; a,b P < 0.0001.
https://doi.org/10.1371/journal.pone.0187252.g001
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analgesic effects reported in cow calves and because of the avoidance of any influence in bio-
availability and drug distribution, due to other routes of administration [19,21,45].
Pain assessment in ruminants represents a true challenge for clinicians in field. Typically,
prey in their natural state, they tend not to express pain to limit vulnerability [32]. Although
some behavioural indices to assess the pain perception in cattle have been already developed
[7], only the “UNESP-Botucatu unidimensional composite pain scale” has been validated for
postsurgical pain assessment in dairy cows so far [32]. Thus, in buffaloes the lack of specific
pain score scale has forced us to use the model created for dairy cows. Pain stimulus caused by
castration is often associated to physiological, behavioral and neuroendocrine changes [7].
Indeed, after the release of pro-inflammatory cytokines and the consequent activation of the
hypothalamus-pituitary-adrenal axis, the sympathetic nervous system bring to the release of
ACTH and catecholamines [46]. An increase of the myocardial activity and the peripheral
vasoconstriction are the main effects raised by this neuroendocrine activity followed by a
higher oxygen request generating an increase of RR and HR, as consequence [46]. Thus, these
clinical parameters can be considered an indirect indicator of pain. The significant lower RR
values observed in TG than CG may confirm the analgesic effects of meloxicam administrated
in buffalo calves post orchiectomy. The result confirms similar findings observed in cow calves
after dehorning and reporting significant RR decrease in the treated animals [25].
Unlike a similar study based on intravenous administration of meloxicam in dairy calves
during dehorning [21], the HR did not showed any difference between TG and CG. The lack
of difference may be due to the different surgical procedure as well as to the technique used for
Fig 2. Mean meloxicam concentrations (± S.D.) time profile from 0 to 96 h after IV treatment at 0.5 mg/kg in 6 buffalo calves.
https://doi.org/10.1371/journal.pone.0187252.g002
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HR detection; although an adaptation phase has been introduced, the handling of the animals,
necessary for parameter detection, may have reduced the difference between the two groups.
Probably, the use of different recording systems such as digital Holter, already used in farm
animals for scientific purposes, may allow a correct detection over-time HR, reducing the neg-
ative effects due to investigators presence [47].
Regarding the body temperature, the administration of meloxicam did not produce any sig-
nificant difference between the two groups confirming similar finding recently observed in
beef bull calves submitted to surgical castration [48]. The correct application of the good clini-
cal practices may explain the results observed. As described by Desrosches [29], the respect of
high hygiene standards pre-, during- and post-surgical procedures may significantly reduce
risk of secondary infection during the follow-up period. Although no significant differences
have been observed between the two groups, a moderate correlation between T and SCL have
been found only in CG. The difference may be explained considering that the decreasing curve
of the values of both the parameters (T and SCL) in this group was likely more similar than
those observe in TG were the SCL decrease more quickly.
Finally, the overall significant difference observed between TG and CG regarding the PS
seemed to confirm the painkiller properties of the NSAIDs allowing a reduction of pain behav-
iours. Although the surgical procedure produced a series of behavioural changes in both
groups, treated animals were also scored significantly lower than the untreated, when com-
pared with their respective T0 (pre-surgery) further supporting the hypothesis. Moreover, the
Table 2. Mean and S.D. of meloxicam pharmacokinetic parameters after IV administration at 0.5 mg/
kg in 6 buffalo calves.
Parameters Unit Mean S.D.
AUC (0!1) h* μg/mL 118.81 27.57
t ½ K10 h 6.93 3.66
t ½ α h 0.09* 0.06
t ½ β h 21.51* 6.4
K10 1/h 0.13 0.09
K12 1/h 4.18 2.89
K21 1/h 1.75 1.61
C0 μg/mL 14.39 7.13
V1 mL/kg 40.51 15.16
ClB mL/h/kg 4.38 0.95
AUMC(0!1) h*h* μg/mL 3991.78 1859.87
MRT(0!1) h 32.89 10.33
Vdss mL/kg 142.31 55.08
V2 mL/kg 101.8 67.31
Vz mL/kg 146.16 53.98
AUC (0-1) = area under serum concentration-time curve from 0 extrapolated to infinity; t ½ K10 = the half-life
associated with the rate constant K10; t ½α = distribution half-life; t ½β = elimination half-life; K10 = the rate
at which the drug leaves the system from the central compartment (the elimination rate); K12 = the rate at
which the drug passes from central to peripheral compartment; K21 = the rate at which the drug passes from
peripheral to central compartment; C0 = serum concentration at time 0; V1 = volume of distribution in the
central compartment; ClB = body clearance; AUMC = area under moment curve; MRT = mean residence
time; Vdss = volume of distribution at steady-state; curve; V2 = volume of distribution in the peripheral
compartment; Vz = volume of distribution based on the terminal phase;
* = harmonic mean ± pseudo-deviation standard.
https://doi.org/10.1371/journal.pone.0187252.t002
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significant correlations observed between PS and SCL in both the groups may confirm the reli-
ability of this composite pain scale for assessing postoperative pain also in buffaloes.
Concerning the SCL, the parameter showed lower overall mean values in TG than CG, as
observed also by Coetzee at al. [21] in animals after dehorning. Moreover in our study,
although both groups achieved a SCL peak 30 min post-orchiectomy, the TG showed a faster
and significant decrease of SCL (T4 h) than CG in which analogous values were reached only
the day after (T 24 h) (Fig 1). The results seem to confirm how meloxicam may have inhibitory
effects on the COX iso-enzymes also in buffalo as in cow, reducing the pain perception, subse-
quent stress with positive effects on the animal welfare; indeed, a significant decrease of SCL
after stressors action (e.g. orchiectomy), can protect the animals against its immunosuppres-
sive effects, reducing their long-term susceptibility to infections [23].
The pharmacokinetics of meloxicam after oral and IV administration has been first
described by Coetzee at al. 2009 [19] in calves. A mean peak plasma concentration (Cmax) of
3.10 μg/mL (range 2.64–3.79 μg/mL) was recorded at 11.64 h (range 10–12 h) with an elimina-
tion half-life of 27.54 h (range 19.97–43.29 h) after oral meloxicam administration at 1 mg/kg.
After IV administration at 0.5 mg/kg the elimination half-life and ClB were 20.35 h (range
17.84–22.76 h) and 6 mL/kg/h (range 4.8–7.2 mL/kg/h), respectively, whereas, Vdss and MRT
were 171 mL/kg (range 151–189 mL/kg) and 28.19 (range 24.65–31.58), respectively [19].
The pharmacokinetic profile of meloxicam in buffalo was characterized by a fast distribu-
tion half-life (0.09 ± 0.06 h) and slow elimination half-life (21.51 ± 6.4 h) and after a single IV
injection meloxicam was quantifiable for several days with a mean concentrations of
0.18 ± 0.14 μg/mL at 96 h. Despite the young age of our buffaloes and the presumable variable
metabolic capacity, the low Vdss and ClB values were reasonably homogenous among individu-
als, with values of 142.31 ± 55.08 mL/kg and 4.38 ± 0.95 mL/kg/h, respectively. As reported for
cows, the high protein binding of meloxicam (96.5–98%) [49] can justify the limited volume of
distribution observed in our buffalo calves; this binding can cause relatively low drugs distribu-
tion into the interstitial fluids but facilitates passage into areas of inflammation with leakage of
plasma proteins into exudate [50].
The low ClB, is responsible for the quite long elimination half-life and is influenced by the
hepatic metabolism, that is necessary for meloxicam elimination from the body [51]. The Vdss
(142.31 ± 55.08 mL/kg) was very similar to the Vz (146.16 ± 53.98 mL/kg). Thus, in our buffa-
loes minimal amounts of meloxicam were eliminated during the distribution phase.
The pharmacokinetic profile observed in buffaloes was quite similar to that observed more
recently in Holstein calves undergoing dehorning by Coetzee et al. [21] after IV administration
of 0.5 mg/kg. The distribution half-life was shorter in buffaloes than in calves (0.09 ± 0.08 vs.
0.22± 0.087 h), ClB was more rapid in Holstein calves (6.64 ± 0.76 vs. 4.38 ± 0.95 mL/h/kg), but
elimination half-lives and MRT were comparable (t½β 21.86 ± 3.03 in calves and 21.51 ± 6.4 h
in buffaloes; MRT 31.24 ± 4.37 in calves and 32.89 ± 10.33 h in buffaloes). Volumes of distribu-
tion were higher in Holstein calves (Vdss 193.94 ± 10.34 vs. 142.31 ± 55.08 mL/kg; V1
94.88 ± 9.04 vs. 40.51 ± 15.16 mL/kg), whereas AUC was higher in buffaloes (118.81 ± 27.57
vs. 81.08 ± 10.58 h μg/kg). The results in buffaloes were comparable also to those first pub-
lished calves after IV administration at the same dose by Coetzee et al. 2009 [19], thus, the
assumption that genetic and physiological differences between buffalo (Bubalus bubalis) and
cattle (Bos Taurus) can have a significant impact on pharmacokinetics [52,53] was not
completely confirmed in our study with meloxicam, although this evaluation could have been
limited by the reduced number of animals treated (n = 6).
The association of the positive effects as painkiller together with the pharmacokinetic profile
of meloxicam indicate that this drug can have effects for several days in buffalo calves. In our
study, meloxicam was administered immediately after surgery, but to optimize the perioperative
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analgesia and in agreement with a pre-empitive analgesia, meloxicam could be administered IV
to buffaloes 20–30 min before surgery. No studies have been published on effective plasma con-
centration (EC50) of meloxicam in cattle, whereas in horse and dog meloxicam EC50 was
reported of approximately 0.2 and 0.36 μg/kg, respectively [54,55]. Although with obvious limi-
tations, when considering these concentrations effective also for our buffaloes, they were main-
tained for more than two days in our study following IV administration of meloxicam at 0.5
mg/kg. However, it has to be further investigated, if NSAIDs effects are directly related to
plasma drug concentrations and the real effective values in cattle and buffalo.
Conclusion
The IV administration of meloxicam at 0.5 mg/kg b.w. in Mediterranean buffalo calves, shows
encouraging effects represented by significant and prolonged analgesic effects, significant
reduction of serum cortisol level as well as similar pharmacokinetic profile to bovine calves.
Assessment of meloxicam effects and pharmacokinetics on a larger and different population,
by different routes of administration and with other painful distresses or surgical procedures
needs further scientific attention to fully understand its inclusion in the therapeutic
approaches of these ruminants.
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